- Home
- FCO vs MCRB Comparison
FCO vs MCRB Comparison
Compare FCO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- MCRB
- Stock Information
- Founded
- FCO 1991
- MCRB 2010
- Country
- FCO United Kingdom
- MCRB United States
- Employees
- FCO N/A
- MCRB N/A
- Industry
- FCO Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- MCRB Health Care
- Exchange
- FCO Nasdaq
- MCRB Nasdaq
- Market Cap
- FCO 78.3M
- MCRB 72.0M
- IPO Year
- FCO N/A
- MCRB 2015
- Fundamental
- Price
- FCO $6.23
- MCRB $7.06
- Analyst Decision
- FCO
- MCRB Hold
- Analyst Count
- FCO 0
- MCRB 5
- Target Price
- FCO N/A
- MCRB $73.67
- AVG Volume (30 Days)
- FCO 100.1K
- MCRB 93.5K
- Earning Date
- FCO 01-01-0001
- MCRB 05-07-2025
- Dividend Yield
- FCO 14.96%
- MCRB N/A
- EPS Growth
- FCO N/A
- MCRB N/A
- EPS
- FCO 0.43
- MCRB 8.98
- Revenue
- FCO N/A
- MCRB N/A
- Revenue This Year
- FCO N/A
- MCRB N/A
- Revenue Next Year
- FCO N/A
- MCRB N/A
- P/E Ratio
- FCO $12.30
- MCRB $0.84
- Revenue Growth
- FCO N/A
- MCRB N/A
- 52 Week Low
- FCO $4.73
- MCRB $6.53
- 52 Week High
- FCO $6.63
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- FCO 54.54
- MCRB 39.05
- Support Level
- FCO $6.14
- MCRB $6.84
- Resistance Level
- FCO $6.30
- MCRB $7.33
- Average True Range (ATR)
- FCO 0.12
- MCRB 0.57
- MACD
- FCO -0.01
- MCRB 0.10
- Stochastic Oscillator
- FCO 32.14
- MCRB 29.44
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.